Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Kraft: Consolidated Half-year Sales Mark ¥13.5 Bil.
January 1, 2001
-
ARCHIVE Additional Safety Measures for Bio-Vascular's Artificial Blood Vessel Ordered
January 1, 2001
-
ARCHIVE Perspective for the Japanese Pharmaceutical Industry in 2001
January 1, 2001
-
ARCHIVE AstraZeneca K.K.
January 1, 2001
-
ARCHIVE DIAGNOSTIC NEWS IN BRIEF
January 1, 2001
-
ARCHIVE Sankyo to Codevelop Oral Antithrombotic with Lilly
January 1, 2001
-
ARCHIVE Long-term Administration of PPI Included in Insurance Coverage
January 1, 2001
-
ARCHIVE Aiming at Sales of ¥350 Bil. to ¥400 Bil. in 2005: Mr Bootes of Pfizer
January 1, 2001
-
ARCHIVE Mitsubishi-Tokyo Licenses Antiviral Agent MCC-478 to Eli Lilly
January 1, 2001
-
ARCHIVE Third Parties to Be Allowed to Provide Sperm or Ova for Infertile Couples
January 1, 2001
-
ARCHIVE Taisho Licenses CRF Receptor Antagonist to Janssen
January 1, 2001
-
ARCHIVE Serious Skin Disorders Caused by Drugs Reported: PMSB
January 1, 2001
-
ARCHIVE BMS Creates Bristol Pharmaceuticals, Spliting Off Its Pharm. Div.
January 1, 2001
-
ARCHIVE Promotion of Genomic Research Recommended by Deregulation Panel
January 1, 2001
-
ARCHIVE BASF Sells Pharma Business to Abbott
January 1, 2001
-
ARCHIVE RESEARCH AND DEVELOPMENT NEWS IN BRIEF
January 1, 2001
-
ARCHIVE Takepron Approved for Maintenance Therapy of Recurrent Reflux Esophagitis
January 1, 2001
-
ARCHIVE Business of Major Drugstore Chain Operators Continues to Expand
January 1, 2001
-
ARCHIVE JPMA to Work More Closely with Patients' Organizations
January 1, 2001
-
ARCHIVE Matsumotokiyoshi: Consolidated Half-year Sales Reach ¥115 Bil.
January 1, 2001
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…